pISSN 1226-6051
eISSN 2508-786X

Table. 1.

Table. 1.

Baseline characteristics

Population descriptionm, Median (Minimum-Maximum) [N (%)] Characteristics for all patients (N=133) Characteristics for subgroup patients (N=62, no history of Diabetes and concomitant therapy) Characteristics for subgroup patients (N=42, Pearson coefficient > |0.7|)
Age, years (range) 68 (36–93) 70 (45-86) 68.5 (47-82)
Sex, male 97 (72.9) 49 (79.0.3) 27 (64.3)
Weight, kg (range) 60.5 (37.1–97.5) 59.43 (37.1-97.5) 60.85 (41.96-88.5)
BMI, kg/m² (range) 22.8 (14.66–36.09) 22.84 (14.66-36.09) 24.06 (17.76-36.09)
BMI, kg/m2 (categorized)
Underweight (<18.5) 14 (10.53) 7 (11.29) 4 (9.52)
Normal (≥18.5, <23) 56 (42.1) 25 (40.32) 12 (28.57)
Overweight (≥23, <25) 27 (20.3) 13 (21.0) 12 (28.57)
Obese (≥25) 36 (27.06) 17 (27.42) 14 (33.33)
Cancer type
Lung 81 (60.9) 42 (67.74) 23 (54.76)
Melanoma 20 (15.0) 5 (8.06) 10 (23.8)
Others 19 (14.4) 15 (24.20) 9 (21.43)
Baseline blood glucose, mg/dl (range) 118 (77-546) 114 (81-243) 134 (77-282)
< 130 79 42 (67.74) 20 (47.62)
≥ 130 54 20 (32.26) 22 (52.38)
History of diabetes 31 (23.3) - 12 (28.57)
Treatment of diabetes 27 (20.3) - 8 (19.04)
Concomitant steroid therapy
Prophylactic 26 (50) - 8 (42.1)
Intervention 23 (44) - 10 (52.63)
Unknown 1 (1.9) - 1 (5.26)
None 81 (60.9) - 23 (54.76)
Pembrolizumab therapy
Administration days (range) 74 (14–998) 85 (20-998) 96 (40-750)
Number of cycles (range) 4 (2–48) 5 (2-48) 5.5 (3-36)
Cumulative dose for 100 days, mg 580 (200–1000) 595.3 (200-1000) 600 (258.8-1000)
Mean dose per cycle for 100 days, mg/kg/cycle 2.53 (1.7–4.88) 2.58 (1.78-4.88) 2.14 (1.79-4.4)
Korean J Clin Pharm 2021;31:237-46 https://doi.org/10.24304/kjcp.2021.31.3.237
© 2021 Korean J Clin Pharm